Peptide longevity: what the evidence shows

Peptides promoted for longevity and healthspan span an enormous range of evidence quality. At one end sits a class of drugs that have run 17,000-patient randomised controlled trials with hard cardiovascular endpoints. At the other sits a tetrapeptide whose only human-cell data comes from a single 2003 in vitro experiment. The gap matters when anyone is trying to weigh what a compound might do for them versus what marketers say it will.

This article maps the evidence quality for each major candidate in the longevity conversation. The goal is to help a scientifically literate reader calibrate how much weight to put on a given claim.

The strongest evidence: GLP-1 receptor agonists and cardiovascular outcomes

If any peptide class has a legitimate claim to longevity-adjacent effects, it is the GLP-1 receptor agonists. The SELECT trial enrolled 17,604 adults aged 45 and older with established cardiovascular disease, obesity (BMI 27 or above), and no diabetes. Participants received semaglutide 2.4 mg weekly or placebo for a mean of 39.8 months. The primary composite endpoint, cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, occurred in significantly fewer patients on semaglutide (hazard ratio 0.80; 95% CI 0.72 to 0.90; P less than 0.001)^[1]. That is a 20% relative reduction in major adverse cardiovascular events in a population without diabetes.

The SELECT finding is the most important cardiovascular outcome result for any peptide in the longevity literature. The evidence grade is Tier 1 by any standard: a pre-registered, peer-reviewed Phase 3 RCT published in the New England Journal of Medicine with a hard composite endpoint. The mechanism is partly weight loss and partly direct cardiometabolic effects on inflammation, blood pressure, and lipids. The trial did not set out to measure lifespan extension, and we should not describe it that way. What it showed is that semaglutide meaningfully reduces the near-term risk of dying from a cardiovascular event in people with obesity and pre-existing heart disease. That is cardiometabolic risk reduction, not longevity in the speculative sense.

A companion data point: the SUMMIT trial tested tirzepatide in 731 patients with heart failure with preserved ejection fraction and obesity. Cardiovascular death or worsening heart-failure events occurred in 8.0% of the tirzepatide group versus 14.2% on placebo (hazard ratio 0.62), with significant quality-of-life improvements at a median of 104 weeks. Again, this is disease-specific outcome data, not lifespan research. But it is the kind of hard-endpoint evidence that most peptides marketed for longevity will never produce.

Growth hormone secretagogues: the evidence gap

Tesamorelin and ipamorelin both work on the growth hormone axis, and both get discussed in longevity circles on the basis that higher GH and IGF-1 correlate with better body composition and, in some animal data, extended lifespan. The actual clinical evidence is narrower.

Tesamorelin is FDA-approved for one indication: HIV-associated lipodystrophy. Its phase-3 trials showed reduction in visceral abdominal fat in that specific population on a specific dose. Off-label use for body composition or longevity in healthy adults has not been studied in any published RCT. For tesamorelin specifically, the longevity claim rests on a mechanism (raising endogenous GH and IGF-1) rather than an outcome trial.

Ipamorelin has been characterised in human pharmacokinetic studies. A 1999 PK/PD study in healthy male volunteers demonstrated dose-proportional GH release with a terminal half-life of approximately two hours^[5]. The finding confirms the compound does what it is supposed to at the pharmacokinetic level. What it does not provide is any evidence for clinically meaningful longevity or healthspan benefit in humans. There are no published phase 2 or phase 3 efficacy trials for ipamorelin in any indication. The FDA's Pharmacy Compounding Advisory Committee reviewed ipamorelin in 2024 without recommending it for compounding use under section 503A.

A note on IGF-1: the growth hormone axis is a double-edged sword in longevity biology. Animal models with reduced GH and IGF-1 signalling (Ames dwarf mice, Laron syndrome cohorts) often live longer, not shorter. The longevity case for raising IGF-1 via secretagogues is contested even in theory, not just in the absence of trial data.

Epitalon and GHK-Cu: preclinical signals with no human trial data

Epitalon (also spelled Epithalon; the tetrapeptide AEDG) is the compound most directly marketed for telomere-based longevity. The foundational published result is a 2003 in vitro study by Khavinson et al. showing that adding Epitalon to telomerase-negative human fetal fibroblast cultures induced telomerase activity and telomere elongation^[2]. A 2025 review in the International Journal of Molecular Sciences covers 25 years of research on the compound and describes geroprotective and neuroprotective signals, including effects on melatonin synthesis and immune markers, but acknowledges 'it remains uncertain whether these are the sole mechanisms of action' and that human clinical trial data is absent^[3].

The honest summary on Epitalon: the in vitro and animal data is interesting, the mechanistic story is plausible, and there is no RCT in humans for any longevity endpoint. Vendors marketing it as a lifespan-extending compound are extrapolating far beyond the literature.

GHK-Cu is a naturally occurring copper-binding tripeptide that has been studied for wound healing, skin aging, and more recently, gene expression effects. A 2018 narrative review by Pickart and Margolina summarised preclinical data showing anti-inflammatory signalling, tissue repair across multiple organ systems, and modulation of pathways associated with aging^[4]. The review argues that GHK may influence gene expression in a pro-repair direction. Again, these findings come from in vitro and animal models. There are no published phase 2 or phase 3 RCTs of GHK-Cu for aging or longevity in humans.

How to read evidence tiers

When a vendor or content creator cites 'research' on a longevity peptide, the first question is what kind. The hierarchy runs: in vitro at the bottom, then animal models, then uncontrolled human case series, then phase 1 or phase 2 trials, then pre-registered phase 3 RCTs with hard endpoints at the top.

Most peptides marketed for longevity sit at tier one or two of that ladder. The GLP-1 agonists are the exception. The correct response to preclinical data is not 'this probably works the same way in humans' but 'this warrants further study.' Those are different statements.

What we don't know yet

No peptide intervention has demonstrated a confirmed effect on human lifespan in a pre-registered controlled trial. The SELECT cardiovascular data is the closest adjacent evidence: a risk-reduction result in a defined high-risk population, not a longevity signal in the general sense. For Epitalon, GHK-Cu, growth hormone secretagogues, and most other compounds in this space, the human trial data does not exist. The mechanism is interesting. The marketing extrapolates far beyond it.

If you are reading coverage of peptides for longevity, the most useful question to ask of any source is: what is the study design and the endpoint, and was it conducted in humans? Most of the time, the answer will make the headline considerably less certain.